fashion -WSS

fashion

author：leisure time 2025-10-03 01:04:06 - browse：46

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： FDA greenlights medical device to combat bladder issues

WSS

Physicians and social media: If you see something, say something?

Colonoscopy prep: Liquid

Abortion policy in the spotlight at Republican debate

5 to watch: Tech startups trying to solve health care's staffing crisis

Intellia plays down concerns on accidental germline transmission

Readout Newsletter: Bluebird, CVS, Contineum

Wikipedia

fashion

knowledge

Moonlake's readout produced a cash windfall. Risks remain

PBMs are inflating the cost of generic drugs. They must be reined in

BioMarin wins approval for gene therapy to treat hemophilia A

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Anesthesiologist group: stop taking Ozempic before surgery

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

ChatGPT in medicine: STAT answers readers' burning questions

How the drug

Medical leaders decry Supreme Court decision on affirmative action

Gene editing the human germline: What are the risks?

focus

Nurses recount patients attacks

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

SCOTUS questions limit to govt efforts to fight misinformation

Abortion policy in the spotlight at Republican debate

Intellia plays down concerns on accidental germline transmission

How the first Native Hawaiian psychiatrist helped diversify medicine

hotspot

leisure time

Wikipedia

focus